Immatics (IMTX) has released an update.
Immatics N.V., a foreign private issuer, has announced the immediate appointment of Alise Reicin as a temporary non-executive director to its Board of Directors. Reicin brings a wealth of experience, including her current role as CEO of Tectonic Therapeutic and past positions at Celgene Corporation and EMD Serono. Her extensive background in clinical development and leadership in the biotech sector will serve Immatics until her anticipated formal appointment at the 2025 Annual General Meeting.
For further insights into IMTX stock, check out TipRanks’ Stock Analysis page.
